The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
[Source] Injury Conditions That Respond Best to BPC157 Meniscus tears & ligament strains Rotator cuff or labrum injuries Elbow and wrist inflammation Early cartilage degeneration How to Use BPC157 for Joint Pain Typical dosage: 300500 g , injected 23 times/week Cycle: 8 weeks on, 8 weeks off (Huberman-recommended) Injection: Subcutaneouslyeither in belly fat or near the injured joint [Huberman Lab Dosage & cycling] Combining BPC157 With Other Recovery Tools Stack with TB500 for enhanced soft tissue healing Use collagen, vitamin C, and omega3s to support structural regeneration What to Expect: Timeline for Healing Safety and Side Notes Side effects: rare but monitor reactions Do not use if you have or are at risk of tumors (angiogenesis caution) Use only peptides from trusted, lab-tested sources FAQs About BPC157 and Joint Pain Can it help old injuries
Reduces the frequency of flu-like symptoms in adults over 65
Our recommended milk thistle supplements from Life Extension, NOW Foods, and HUM Nutrition exceed that amount
